Nektar Therapeutics said its net loss for the first quarter was 60 cents per share, compared with the S&P Capital IQ consensus normalized EPS estimate of a loss of 55 cents per share.
The per-share loss grew 42.9% year over year from 42 cents.
Net loss totaled $95.8 million, compared with a loss of $63.9 million in the prior-year period.
In April, the company completed a multibillion-dollar strategic development deal with Bristol-Myers Squibb Co. The company said the proceeds from the deal were not included in this quarter's reporting.
Total revenue grew 53.7% on an annual basis to $38.0 million from $24.7 million, and total operating costs and expenses climbed 57.6% year over year to $124.8 million from $79.2 million.
